IHI Exports 250,000 Tylenol Units to South Korea Worth Rp 2.4 Billion

JAKARTA, Investortrust.id — PT Integrated Healthcare Indonesia or IHI exports 250,000 units of Tylenol worth Rp 2.4 billion, equal to $150,000, to South Korea on Friday, Feb 13, 2026 in Jakarta to strengthen Indonesia’s role in the global pharmaceutical supply chain, as the government pushes export expansion and technology transfer to enhance industrial competitiveness.

The shipment was released from the company’s production facility in Jakarta as part of efforts to deepen market penetration in Northeast Asia and expand export-oriented manufacturing.

The Director General of National Export Development at the Trade Ministry, Fajarini Puntodewi, attended the ceremony and praised IHI’s contribution to national pharmaceutical exports.

"We appreciate PT IHI for its hard work and contribution to Indonesia’s pharmaceutical export performance. Today, 250,000 units of pain relief medicine are shipped to South Korea, demonstrating Indonesia’s production capability in the global supply chain," Puntodewi said in a written statement on Saturday, Feb 14, 2026.

She urged the company to continue strengthening production capacity and knowledge transfer to domestic industry players.

"In addition to increasing production volume, strengthening knowledge and technology transfer to domestic industry players is crucial to ensure the national pharmaceutical industry becomes more competitive," she added.

IHI operates as a manufacturing facility under Johnson & Johnson’s former consumer health business, now part of Kenvue Inc., a United States-based global consumer health company.

According to Puntodewi, Kenvue’s presence in Indonesia reflected growing global investor confidence in the country’s business climate.

Bonded zone facility

The export marked a strategic milestone after IHI obtained bonded zone status from the Directorate General of Customs and Excise on Dec 16, 2025.

The bonded zone facility, which allows duty and tax incentives for export-oriented manufacturers, was expected to improve cost efficiency and accelerate production and export processes.

Derry Arifin, Head of Customs and Excise Services Section V at the Jakarta Customs Office, said the bonded zone status provided fiscal and customs facilities, including tax restitution.

"After obtaining this facility, the company is entitled to customs and tax incentives, including tax restitution, which can be reused to purchase raw materials and support operational needs, thereby enhancing competitiveness in export markets," Derry said.

IHI Director Teerasak Luewirat welcomed the regulatory support and collaboration between the government and industry.

"We highly appreciate the collaboration, regulatory support, and partnerships from all stakeholders. We hope this synergy continues to grow so that we can drive economic growth and strengthen Indonesia’s position in the global trade ecosystem," he said.

Statistics Indonesia reported that pharmaceutical exports grew 7.63 percent during the 2021–2025 period.

In 2025, South Korea ranked as Indonesia’s third-largest pharmaceutical export destination with export value reaching $75.46 million, accounting for 10.24 percent of total national pharmaceutical exports.

Globally, pharmaceutical demand expanded 11.02 percent during 2020–2024, with global industry revenue reaching $1.16 trillion in 2024 and projected to rise to $1.53 trillion by 2030, offering wider opportunities for Indonesia to scale up production and trade participation.